# Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

> **NCT04586543** · PHASE2 · UNKNOWN · sponsor: **László Mangel** · enrollment: 110 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer
- Adenocarcinoma of the Prostate

## Interventions

- **DRUG:** Selegiline
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04586543
- **Lead sponsor:** László Mangel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-18
- **Primary completion:** 2025-02-01
- **Final completion:** 2025-02-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2020-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04586543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04586543, "Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04586543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*